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Among 176 patients who had had severe acute respi-
ratory syndrome (SARS), SARS-speciﬁ   c antibodies were 
maintained for an average of 2 years, and signiﬁ  cant re-
duction of immunoglobulin G–positive percentage and titers 
occurred in the third year. Thus, SARS patients might be 
susceptible to reinfection >3 years after initial exposure. 
S
evere acute respiratory syndrome (SARS) represents 
the ﬁ  rst pandemic transmissible disease to emerge in 
this century. It was caused by a previously unknown coro-
navirus, the SARS-associated coronavirus (SARS-CoV) 
(1). SARS-CoV spreads from animals to humans by a rapid 
adaptation and evolution process (2,3). A large number 
of closely related viruses are present in wildlife reservoir 
populations (4–6). Therefore, due to cross-species trans-
mission of the same or a similar coronavirus, SARS could 
recur. Immune protection against infection with other hu-
man coronaviruses, such as OC43 and 229E, is short-lived 
(7). To assess SARS patients’ risk for future reinfection, 
we conducted a longitudinal study of immunity in conva-
lescent patients.
The Study
Shanxi Province in China was 1 of the SARS epicen-
ters during the 2002–03 outbreaks. For our study, serum 
samples were taken from patients in 7 designated SARS 
hospitals in the province during March–August 2003. Fol-
low-up serum samples were taken at 6 months, 1, 2, and 3 
years after the onset of symptoms. A total of 176 cases that 
met the World Health Organization (WHO) SARS case 
deﬁ  nition (8) and had known transmission history were in-
cluded in this study. The study was conducted as part of 
a national SARS control and prevention program; use of 
serum from human participants was approved by the Com-
mittee for SARS Control and Prevention, Department of 
Science and Technology, the People’s Republic of China.
Titers of serum antibodies to SARS-CoV were deter-
mined by using a commercially available ELISA kit (BJI-
GBI Biotechnology, Beijing, China). The ELISA was based 
on an inactivated preparation of whole-virus lysate. The kit 
was the ﬁ  rst commercial kit approved by the Chinese Food 
and Drug Administration for speciﬁ  c detection of SARS-
CoV antibodies and has been widely used in several studies 
(9–11). Manufacturer’s instructions were followed without 
modiﬁ  cation. Brieﬂ  y, for every ELISA plate, 1 blank, 1 
positive, and 2 negative controls were included. For detec-
tion of immunoglobulin G (IgG), a 1:10 dilution of testing 
serum (100 μL) was added to antigen-coated wells, and the 
plate was incubated at 37oC for 30 min. Horseradish perox-
ide (HRP)–conjugated antihuman IgG (100 μL) was then 
added for detection of bound antibodies. For detection of 
IgM, the incubation of primary antibodies was extended to 
60 min, followed by detection with HRP-conjugated anti-
human IgM. Optical density (OD) readings were deemed 
valid only when the negative control OD was <0.10 and 
the positive control was >0.50 on the same ELISA plate. 
The cutoff for IgG and IgM determination was deﬁ  ned as 
0.13 and 0.11, respectively, plus OD of the negative con-
trol. When the OD of the negative control was <0.05, 0.05 
was used for the calculation. In this study, the OD read-
ings of negative controls from different testing were con-
sistently <0.05, so the cutoff ODs for IgG and IgM were 
0.18 and 0.16, respectively. Serum samples that had an OD 
greater than or equal to the cutoff value were considered 
positive. Weak positive samples (i.e., OD<2× cutoff value) 
were retested in duplicate on the same day; only reproduc-
ible positive results were included in the ﬁ  nal analysis. All 
data were processed by using Excel version 7.0 (Microsoft 
Corp., Redmond, WA, USA) and SPSS software version 
10 for Windows (SPSS Inc., Chicago, IL, USA).
Among the cohort, 163 (92.61%) of 176 (χ2 = 200.11, 
p = 0.000002) were IgG positive, which indicated that most 
patients who met the WHO case deﬁ  nition were indeed 
infected with SARS-CoV. As shown in the Table, at ≈7 
days after the onset of symptoms, the percentage who were 
IgG positive was ≈11.80%. This percentage continued to 
increase, reached 100% at 90 days, and remained largely 
unchanged up to 200 days. Furthermore, after 1 and 2 years 
93.88% and 89.58% of patients, respectively, were IgG 
positive, which suggests that the immune responses were 
maintained in >90% of patients for 2 years. However, 3 
years later, ≈50% of the convalescent population had no 
SARS-CoV–speciﬁ  c IgG. The OD changes correlated with 
the changes to the IgG-positive percentage, although the 
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rate of change varied. Both the OD readings (0.93) and pos-
itive percentages peaked at 90–120 days; however, the rate 
of reduction of the average OD readings was much faster, 
dropping by 22% (0.73) and 40% (0.54) at 1 and 2 years, 
respectively, after symptom onset (Figure 1).
A similar observation was obtained for IgM trends in 
this same cohort. The percentage of patients who were IgM 
positive within the ﬁ  rst 7 days was 21.4% and peaked at 
76.2% after 21–30 days (Table). The patterns of IgM-posi-
tive percentage and average OD readings were similar; both 
peaked at 21–30 days. After 60 days, the average OD read-
ings dropped to 0.167, close to the cutoff value of 0.160.
Among the cohort of patients with known transmission 
histories, we were able to obtain a complete collection of 
serum samples from 18 patients at 6 months, 1, 2, and 3 
years. The IgG levels of these 18 patients were analyzed 
separately to obtain an IgG trend that more accurately rep-
resented convalescent SARS patients (Figure 2). All 18 
patients had positive IgG at 6 months and at 1 year (i.e., 
100% positive); only 1 patient became IgG negative at 2 
years. However, at 3 years, the positive percentage dropped 
to 55.56%. The reduction of OD values mimicked that of 
the positive percentage, again at a faster rate. The average 
OD readings dropped from 0.94 at 6 months to 0.64 at 1 
year, which represents a reduction of 33.33%. The OD fur-
ther dropped to 0.52 (45.83% reduction) by 2 years and to 
0.25 by 3 years.
Conclusions
To our knowledge, the 3-year follow-up conducted in 
this study is the longest longitudinal study ever reported. 
With a large number of patients who had conﬁ  rmed trans-
mission history (176) and a complete dataset for 18, the 
level of conﬁ  dence is high that the results obtained in this 
study are representative for convalescent SARS patients. 
Similar results have been reported from longitudinal stud-
ies of SARS patients with smaller cohort size (18–98 pa-
tients) and shorter follow-up period (240 days to 2 years) 
(9–14). The general trend of IgM peaking at ≈1 month after 
symptom onset and IgG peaking at 2–4 months was consis-
tent among different studies. 
Our results provide strong evidence that SARS-CoV 
antibodies are reduced >3 years after the symptom onset. 
Because antibodies play an important role in protective 
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Table. Cumulative rates of SARS-CoV antibodies among 176 SARS patients with known transmission histories*  
IgG IgM†
Time after 
symptom onset, d 
No. samples 
tested
No. positive 
samples (%)  Average OD
No. samples 
tested
No. positive 
samples (%)  Average OD
0–7 17 2 (11.76)  0.046 14 3 (21.43)  0.136
8–14 26 10 (38.46)  0.190 22 14 (63.64)  0.312
15–20 22 17 (77.27)  0.351 19 12 (63.16)  0.477
21–30 36 33 (91.67)  0.493 21 16 (76.19)  0.560
31–60 72 67 (93.06)  0.627 22 14 (63.64)  0.320
61–90 35 33 (94.29)  0.745 15 5 (33.33)  0.167
91–120 11 11 (100.00) 0.965 ND ND ND
121–210 23 23 (100.00) 0.932 ND ND ND
211–365 49 46 (93.88) 0.734 ND ND ND
366–763 96 86 (89.58) 0.535 ND ND ND
764–1,265 28 15 (53.57) 0.250 ND ND ND
*SARS-CoV, severe acute respiratory syndrome–associated coronavirus; Ig, immunoglobulin; OD, optical density; ND, not determined because for most 
samples the IgM readings already reached background level on day 90. 
†For some patients, we did not have enough serum to test for IgM after testing for IgG; hence, a smaller number of serum samples were tested for IgM 
than for IgG.  
Figure 1. Change of immunoglobulin G (IgG) patterns among 176 
convalescent severe acute respiratory syndrome patients with 
known transmission history. See the Table for number of samples 
used for the calculation at each time point. OD, optical density. 
Figure 2. Change of immunoglobulin G (IgG) patterns among 18 
convalescent severe acute respiratory syndrome patients with 
a complete collection of sequential serum samples at the time 
points shown. The 18 patients were selected from the cohort of 
176 patients for whom transmission history was known. OD, optical 
density.DISPATCHES
immunity against SARS-CoV (15), the ﬁ  ndings from this 
study will have important implications with regard to as-
sessing risk for reinfection among previously exposed pop-
ulations (e.g., hospital staff) and evaluating the duration of 
antibody-mediated immunity that any candidate vaccine 
could provide.
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